- Home
- RARE vs HRMY Comparison
RARE vs HRMY Comparison
Compare RARE & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | HRMY |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RARE | HRMY |
|---|---|---|
| Price | $23.40 | $36.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 8 |
| Target Price | ★ $73.11 | $49.75 |
| AVG Volume (30 Days) | ★ 4.0M | 615.1K |
| Earning Date | 02-12-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | N/A | ★ 3.17 |
| Revenue | $630,598,000.00 | ★ $825,944,000.00 |
| Revenue This Year | $19.68 | $23.29 |
| Revenue Next Year | $19.44 | $15.98 |
| P/E Ratio | ★ N/A | $11.58 |
| Revenue Growth | 20.63 | ★ 21.13 |
| 52 Week Low | $18.41 | $25.52 |
| 52 Week High | $46.50 | $40.93 |
Technical Indicators
Market Signals| Indicator | RARE | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 38.36 | 48.42 |
| Support Level | $22.00 | $35.16 |
| Resistance Level | $24.65 | $37.08 |
| Average True Range (ATR) | 1.28 | 1.43 |
| MACD | 0.19 | -0.21 |
| Stochastic Oscillator | 44.59 | 43.22 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.